Uncategorized Archives - Page 9 of 87 - PsychedelicNewsWire (PNW)

MondayApr 25, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Continues Investor Outreach as Psychedelic Wellness Drug Development Advances

Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal Delic recently received Health Canada authorization to obtain 60 grams of psilocybin…

ThursdayApr 21, 2022 9:00 am

Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?

On March 31, 2022, Silo Pharma (OTCQB: SILO) announced an agreement with contract research organization Frontage Laboratories for an Investigational New Drug (“IND”)-enabling, “Pharmacokinetic Study.” Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Frontage will study Silo’s Central Nervous System Peptide, SPU-16, “a potential new treatment for multiple sclerosis and other conditions,” and their Joint Homing Peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, “enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity….They may be…

WednesdayApr 20, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts

Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic research The company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposes With this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced by them Delic’s management believes that the company is on the cusp of understanding the breadth of what is possible with psychedelics and medicine Back in October 2021, Delic…

MondayApr 18, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent application Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods," further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs. The application covers an array of inhalation delivery…

MondayApr 18, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Continues Expansion to Make Science-Backed Psychedelic Medicines Accessible to Patients with Mental Health Conditions

Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression It is also expanding its ability to research novel compounds and develop IP for future commercialization Delic Holdings' (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Chief Executive Officer (“CEO”) and Co-founder, Matt Stang, has been keen to note the company’s commitment to bringing psychedelic medicine closer to individuals dealing with mental health conditions, particularly those with treatment-resistant…

WednesdayApr 13, 2022 2:52 pm

New Study Highlights How Sleep Patterns Are Impacted by Psilocybin

A new study has found that psilocybin causes temporary changes to the basic structural organization of normal sleep in lab mice. Professor Vladyslav V. Vyazovskiy of the University of Oxford, who conducted the study, stated that evidence had shown that psychedelics such as psilocybin could rapidly reduce core symptoms of various psychiatric conditions, even in serious cases that were resistant to other treatments. The researchers’ objective was to examine the potential impact that psilocybin had on sleep, as sleep disturbance contributed to the continuation as well as the onset of diverse mental illnesses. For their study, the researchers used animal…

WednesdayApr 13, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1 SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far,…

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

MondayApr 11, 2022 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo…

FridayApr 08, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030 One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN)…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized